Clinical trials: Disorder Heart
Coronary Disease, Coronary Artery Disease
SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe
The purpose of this Clinical Evaluation is a continuation in the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of patients with de novo coronary artery…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- SPIRIT V (NCT00402272)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent
- Where
- 93 sites in Austria, Belgium and 21 more
- Volunteers
- 2,700 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease, Renal Impairment
Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography
The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the…
- Trial name
- NCT00209430
- Testing
- Iodixanol 320 mgI/mL
- Where
- Sweden
- Volunteers
- 408 people
- Sponsor
- GE Healthcare
Coronary Artery Disease
Cangrelor Prasugrel Transition Study
To demonstrate that patients treated with cangrelor can be directly switched to oral prasugrel and that patients treated with prasugrel can be switched to cangrelor without a significant decrease in the extent of inhibition of…
- Trial name
- NCT01852019
- Testing
- Cangrelor, Prasugrel
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Medicines Company
Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome
HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt
This is a multi-center, single-blind, randomized, active-controlled, clinical trial in Percutaneous Coronary Intervention (PCI) subjects.
- Trial name
- HARMONEE (NCT02073565)
- Testing
- OrbusNeich Combo stent™, Everolimus Eluting Stent (EES)
- Where
- 50 sites in United States, Japan
- Volunteers
- 572 people
- Sponsor
- OrbusNeich
Heart Septal Defects, Ventricular
Safety and Effectiveness of the Nit-Occlud® Lê VSD Spiral Coil System
The Ventricular septal defect (VSD) is the most common of all congenital cardiac malformations. By modifying the Nit-Occlud® PDA Device the Nit-Occlud® Lê VSD Spiral System was designed.
- Trial name
- pfm-01/2005 (NCT00390702)
- Testing
- transcatheter implantation of a VSD occluder (Nitinol coil)
- Where
- 6 sites in Germany, Israel
- Volunteers
- 103 people
- Sponsor
- pfm medical gmbh
Heart Disease
A Clinical Trial in Higher Risk Geriatric Patients Undergoing OHSP
To provide information on parameters needed to design a subsequent Phase III confirmatory trial and to assess the safety and efficacy of the acute use of CMI X-11S in high-risk geriatric patients undergoing open-heart surgical…
- Trial name
- MiniMetrxics (NCT00500929)
- Testing
- CMI X-11S
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Cardiometabolics
Acute Coronary Syndromes
A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta
To identify the following items through the post marketing surveillance under routine clinical practice after marketing authorization of Brilinta Tablet: the occurrence of unrevealed Serious Adverse Events (SAEs), current status…
- Trial name
- NCT01611272
- Where
- 23 sites in South Korea
- Volunteers
- 3,402 people
- Sponsor
- AstraZeneca
Diastolic Heart Failure
Rheos® Diastolic Heart Failure Trial
The CVRx® Rheos® Diastolic Heart Failure Trial is a prospective, randomized, double blind trial with up to 60 subjects conducted at up to five centers in Europe. All subjects will be followed up to one year post implant.
- Trial name
- NCT00718939
- Testing
- Rheos Baroreflex Activation Therapy System
- Where
- 4 sites in Germany
- Volunteers
- 6 people
- Sponsor
- CVRx, Inc.
Bleeding Disorder, Ischemic Stroke
XIENCE 28 USA Study
The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR)…
- Conditions
- Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases
- Trial name
- NCT03815175
- Testing
- XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 1,605 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation
Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study
To evaluate the safety, tolerability and efficacy of 3 doses of vernakalant (oral) (150 mg, 300 mg and 500 mg b.i.d.) administered for up to 90 days in subjects with sustained symptomatic atrial fibrillation (AF duration > 72…
- Trial name
- NCT00526136
- Testing
- Vernakalant (oral)
- Where
- 152 sites in Australia, Belgium and 22 more
- Volunteers
- 735 people
- Sponsor
- Advanz Pharma
Coagulation, Platelet Function
RapidTEG MA Validation
During normal physiological conditions hemostasis (the ability of blood to clot) is kept in homeostatic balance by feedback mechanisms.
- Trial name
- R-TEG MA (NCT01428102)
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Haemonetics Corporation
Mitral Insufficiency, Heart Valve Disease
Early Feasibility Study of the CardiAQ™ TMVI System (Transfemoral and Transapical DS)
The purpose of the study is to generate early US feasibility data of the CardiAQ™ Transcatheter Mitral Valve Implant System. The study will enroll patients with moderate to severe mitral valve regurgitation who are considered…
- Conditions
- Mitral Insufficiency, Heart Valve Disease, Cardiovascular Disease, Heart Disease
- Trial name
- NCT02515539
- Testing
- CardiAQ TMVI System (Transapical & Transfemoral DS)
- Sponsor
- Edwards Lifesciences
Acute Heart Failure
BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute…
- Trial name
- COMPOSE 1 (NCT01065077)
- Testing
- Cinaciguat (BAY58-2667)
- Where
- 59 sites in United States, Austria and 15 more
- Volunteers
- 12 people
- Sponsor
- Bayer
Primary Ciliary Dyskinesia (PCD)
Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance
This is a multi-dose study with RCT1100 and is designed to provide safety, tolerability and preliminary efficacy data for future clinical studies.
- Trial name
- NCT06633757
- Testing
- RCT1100
- Where
- 3 sites in United States, Denmark and 1 more
- Volunteers
- 14 people
- Sponsor
- ReCode Therapeutics
Cardiac Arrhythmias
EluPro Antibiotic-Eluting BioEnvelope Registry
A Multi-Center Registry Study Evaluating Participants Who Receive EluPro Antibiotic-Eluting BioEnvelope During CIED Implantation
- Trial name
- NCT06854081
- Testing
- EluPro Antibiotic-Eluting BioEnvelope
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Elutia Inc.
Mitral Regurgitation
Safety and Efficacy of the HighLife Transcatherter Mitral Valve Replacement System in Patients With Moderate-severe or Severe Mitral Regurgitation in China
To observe and evaluate the safety and efficacy of the HighLife Transcatheter Mitral Valve Replacement System in patients with moderate-severe or severe mitral valve regurgitation through a prospective, multicenter clinical trial…
- Trial name
- NCT05610566
- Testing
- the HighLife Trans-Septal Transcatheter Mitral Valve Replacement System
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Peijia Medical Technology (Suzhou) Co., Ltd.
Heart Failure, Chronic Disease
Digital Literacy of Chronic Heart Failure Patients
A retrospective cohort study was conducted using a web application (Satelia®Cardio by NP Medical) for the management of chronic heart failure.
- Trial name
- NCT07626853
- Where
- France
- Volunteers
- 26,000 people
- Sponsor
- Satelia
Angimis Atherectomy System is Indicated for CTO, Balloon Failure and ISR in Coronary Arteries Disease
A Prospective, Multicenter, Two-cohorts, Single Arm Study Evaluating Safety, Effectiveness and Performance of Angimis Atherectomy System for the Treatment of Non-crossable and/or Non-dilatablE Lesions in CorONary Arteries Disease (NEON Study).
NEON study is a prospective, multicenter, two-cohorts, single arm study evaluating safety, effectiveness and performance of Angimis Atherectomy System for the treatment of Non-crossable and/or Non-dilatable in Coronary Arteries…
- Trial name
- NEON (NCT07743528)
- Testing
- Adult patient population who have been diagnosed with coronary artery disease with non-crossable and/or non-dilatable lesion which requiring the treatment of PCI
- Volunteers
- 123 people
- Sponsor
- Shenzhen Tonglu Technology Co., Ltd
Heart Failure
Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices
The registry is primarily designed to assess outcome, efficacy and residual safety aspects of CRT based on long-term data from an unselected, real-life clinical set-up.
- Trial name
- BIO|STREAM HF (NCT03366545)
- Testing
- Cardiac Resynchronization Therapy (CRT)
- Where
- 114 sites in Australia, Austria and 18 more
- Volunteers
- 3,030 people
- Sponsor
- Biotronik SE & Co. KG
Mitral Regurgitation, Mitral Insufficiency
MiCLASP Post Market Clinical Follow-Up (PMCF) Study
This is a postmarket clinical follow up study on the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System and the Edwards PASCAL Precision Transcatheter Valve Repair System in transcatheter mitral…
- Trial name
- MiCLASP (NCT04430075)
- Testing
- Edwards PASCAL Transcatheter Valve Repair System and Edwards PASCAL Precision Transcatheter Valve Repair System
- Where
- 37 sites in Austria, Germany and 7 more
- Volunteers
- 1,000 people
- Sponsor
- Edwards Lifesciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.